Abstract
The farnesoid X receptor (FXRα) is a metabolic nuclear receptor and bile acid sensor expressed in the liver and intestine. Physiological studies have shown that FXR.. exerts regulatory roles in bile acids, lipid and glucose homeostasis. FXR ligands of steroidal and non-steroidal structure have been described. Both ligand groups have shown limitations in preclinical studies regarding their absorption, metabolism, target interactions and intrinsic toxicity. Inhibition of bile acid synthesis and basolateral transporters in the liver as well as reduction of high density lipoprotein (HDL) in the plasma are the major unwanted effects seen with these ligands. Several FXRα modulators are currently being generated with the aim of targeting FXRα isoforms by exploiting the relative unselectivity of the ligand binding domain of the receptor. Structure- activity relationship studies have shown that FXRα could be activated by structurally different ligands and that receptor occupancy by these ligands generates different patterns of gene activation as a result of specific conformational changes of the receptor or differential dislodgement of co-repressor or recruitment of co-activators. Generation of modulators that selectively target specific FXRα responsive elements are an interesting strategy to overcome the limitations of currently available FXR ligands.
Current Medicinal Chemistry
Title: Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment
Volume: 17 Issue: 2
Author(s): S. Fiorucci, A. Mencarelli, E. Distrutti, G. Palladino and S. Cipriani
Affiliation:
Abstract: The farnesoid X receptor (FXRα) is a metabolic nuclear receptor and bile acid sensor expressed in the liver and intestine. Physiological studies have shown that FXR.. exerts regulatory roles in bile acids, lipid and glucose homeostasis. FXR ligands of steroidal and non-steroidal structure have been described. Both ligand groups have shown limitations in preclinical studies regarding their absorption, metabolism, target interactions and intrinsic toxicity. Inhibition of bile acid synthesis and basolateral transporters in the liver as well as reduction of high density lipoprotein (HDL) in the plasma are the major unwanted effects seen with these ligands. Several FXRα modulators are currently being generated with the aim of targeting FXRα isoforms by exploiting the relative unselectivity of the ligand binding domain of the receptor. Structure- activity relationship studies have shown that FXRα could be activated by structurally different ligands and that receptor occupancy by these ligands generates different patterns of gene activation as a result of specific conformational changes of the receptor or differential dislodgement of co-repressor or recruitment of co-activators. Generation of modulators that selectively target specific FXRα responsive elements are an interesting strategy to overcome the limitations of currently available FXR ligands.
Export Options
About this article
Cite this article as:
Fiorucci S., Mencarelli A., Distrutti E., Palladino G. and Cipriani S., Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment, Current Medicinal Chemistry 2010; 17 (2) . https://dx.doi.org/10.2174/092986710790112666
DOI https://dx.doi.org/10.2174/092986710790112666 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Metabolomic Insight into Lipid and Protein Profile in Diabetes Using Mass Spectrometry
Mini-Reviews in Medicinal Chemistry Blood Pressure Lowering Treatment in Patients with Carotid Artery Stenosis
Current Hypertension Reviews Diabetes Mellitus: A Potential Target for Stem Cell Therapy
Current Stem Cell Research & Therapy Erythropoietin: New Horizon in Cardiovascular Medicine
Recent Patents on Cardiovascular Drug Discovery Atherogenic Index of Plasma in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus: A 10-Year Potential Predictor of Cardiovascular Disease
Current Rheumatology Reviews The Effects of Herbal Medicines on Women Sexual Dysfunction: A Systematic Review
Current Drug Discovery Technologies Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease
Cardiovascular & Hematological Disorders-Drug Targets Potential Approaches for Beta Cell Imaging with PET and SPECT
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine Protective Potential of Uric Acid, Folic Acid, Glutathione and Ascorbic Acid Against the Formation of Toxic Met-Myoglobin
Protein & Peptide Letters Impact of Mitochondrial Toxicity of HIV-1 Antiretroviral Drugs on Lipodystrophy and Metabolic Dysregulation
Current Pharmaceutical Design The Potential of p38 MAPK Inhibitors to Modulate Periodontal Infections
Current Drug Metabolism The Potential Role of Sirtuins Regarding the Effects of Exercise on Aging- Related Diseases
Current Aging Science Role of Oxidative Stress in Development of Cardiovascular Complications in Diabetes Mellitus
Current Vascular Pharmacology A Systematic Review of the Uterine Relaxant Effect of Herbal Sources
Current Pharmaceutical Biotechnology The Involvement of Uric Acid in the Pathogenesis of Preeclampsia
Current Hypertension Reviews Development and Characterization of Spray Dried Microparticles for Pulmonary Delivery of Antifungal Drug
Current Drug Delivery Evidence for the Involvement of Resistin in Inflammation and Cardiovascular Disease
Current Diabetes Reviews The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Depression and Self-Efficacy in Patients with Type 2 Diabetes in Northern Greece
Endocrine, Metabolic & Immune Disorders - Drug Targets